Reducing LDL Cholesterol

The information on this site is intended for health care professionals in the United States and is not intended for the general public.

I AM A HEALTHCARE PROFESSIONAL I AM NOT A HEALTHCARE PROFESSIONAL
 
Important Information About ZETIA

As an adjunct to diet when diet alone is not enough, for patients on atorvastatin 10 mg not at goal Adding Zetia Delivered SUPERIOR LDL-C Reduction vs Titrating the Statin

This requires Flash to play. Click here to download.

Evaluating the primary end point over the 14-week study duration, 22% of patients reached protocol-specified LDL-C goal (<100 mg/dL) with ZETIA + titrated atorvastatin (up to 40 mg) vs 7% with titrated atorvastatin monotherapy (up to 80 mg).
aStudy Design1: A 14-week, double-blind study (N=621) of patients with heterozygous
familial hypercholesterolemia, coronary heart disease, or >;2 cardiovascular risk factors and
LDL-C >;130 mg/dL on atorvastatin 10 mg. This study compared LDL-C efficacy with response-based titration of atorvastatin 10 mg to 80 mg vs adding ZETIA followed by response-based titration of atorvastatin 10 mg to 40 mg. Mean treated baselines were 186 mg/dL (ZETIA + atorvastatin 10 mg) and 187 mg/dL (atorvastatin monotherapy). Percent changes in LDL-C correspond to mean additional LDL-C reductions of 43 mg/dL with ZETIA + atorvastatin 10 mg and 16 mg/dL with atorvastatin titrated from 10 mg to 20 mg.
 

Important Information About ZETIA

The effect of ZETIA on cardiovascular morbidity and mortality has not been determined.

ZETIA, administered alone or in combination with an HMG-CoA reductase inhibitor (statin), is indicated as adjunctive therapy to diet for the reduction of elevated TOTAL-C, LDL-C, and Apo B in patients with primary (heterozygous familial and nonfamilial) hyperlipidemia when diet alone is not enough.

Contraindications: hypersensitivity to any component of this medication.
Statin contraindications apply when used with a statin: active liver disease; unexplained persistent elevations in hepatic transaminase levels. Statins are contraindicated in pregnant and nursing women. Refer to the statin label for details.

When using ZETIA with a statin, also follow the label recommendations for that specific statin.

Selected Cautionary Information: When ZETIA was coadministered with a statin, consecutive elevations in hepatic transaminase levels (>3 x ULN) were slightly higher (1.3%) than those of statins alone (0.4%). Liver function tests should be performed when ZETIA is added to statin therapy and according to statin recommendations. Should an increase in ALT or AST >3 x ULN persist, consider withdrawal of ZETIA and/or the statin.

Patients should be advised to promptly report muscle pain, tenderness, or weakness. Risk for skeletal muscle toxicity increases with higher statin doses, advanced age (>65), hypothyroidism, renal impairment, and depending on the statin used, concomitant use of other drugs. Discontinue drug if myopathy is diagnosed or suspected.

ZETIA is not recommended in patients with moderate to severe hepatic impairment.

The coadministration of ZETIA with fibrates other than fenofibrate is not recommended until use in patients is adequately studied.

Exercise caution when using ZETIA and cyclosporine concomitantly because exposure to both drugs is increased. Cyclosporine concentrations should be monitored in these patients.

ZETIA should be used in pregnant or nursing women only if the benefit outweighs the risk.

In clinical trials, regardless of causality assessment, the most frequent side effects for ZETIA coadministered with a statin vs statin alone included nasopharyngitis (3.7% vs 3.3%), myalgia (3.2% vs 2.7%), upper respiratory tract infection (2.9% vs 2.8%), arthralgia (2.6% vs 2.4%), and diarrhea (2.5% vs 2.2%); for ZETIA administered alone vs placebo: upper respiratory tract infection (4.3% vs 2.5%), diarrhea (4.1% vs 3.7%), arthralgia (3.0% vs 2.2%), sinusitis (2.8% vs 2.2%), and pain in extremity (2.7% vs 2.5%).

Before prescribing ZETIA, please read the Prescribing Information.

References: 1. Stein E, Stender S, Mata P, et al; for Ezetimibe Study Group. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin. Am Heart J. 2004;148(3):447–455. 2. Data available on request from Merck & Co., Inc., Professional Services-DAP, WP1-27, PO Box 4, West Point, PA 19486-0004. Please specify information package 20705526(2)-ZET.

This site is intended only for health care professionals of the United States, its territories, and Puerto Rico.

For non-US health care professionals, click here.

ZETIA and VYTORIN are registered trademarks of MSP Singapore Company, LLC.
20950796(1)-06/09-ZET